XDH and metabolic dysfunction-associated steatohepatitis: To clarify whether XOR inhibitors can prevent or delay cardiovascular complications associated with increased plasma XOR activity, as in mice, large-scale studies enrolling patients with NAFLD/NASH will be required in the future.